The zinc-metalloenzyme GlcNAc-PI de-N-acetylase is essential for the biosynthesis of mature GPI anchors and has been genetically validated in the bloodstream form of Trypanosoma brucei, which causes African sleeping sickness. We screened a focused library of zinc-binding fragments and identified salicylic hydroxamic acid as a GlcNAc-PI de-N-acetylase inhibitor with high ligand efficiency. This is the first small molecule inhibitor reported for the trypanosome GPI pathway. Investigating the structure activity relationship revealed that hydroxamic acid and 2-OH are essential for potency, and that substitution is tolerated at the 4-and 5-positions.
Introduction
Trypanosoma brucei is a protozoan parasite that is transmitted by the bite of an infected tsetse fly and causes the fatal African sleeping sickness in humans and the related wasting disease Nagana in cattle. Current treatments are expensive, toxic, and difficult to administer, leaving an urgent need for improved therapeutic agents. The parasite is able to evade the host immune response by virtue of a dense surface coat composed of 5 Â 10 6 variant surface glycoprotein (VSG) dimers that prevent lysis by the innate immune response. The coat also undergoes antigenic variation to evade the adaptive immune response. 1 The VSG dimer is attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor, and GPI anchor biosynthesis has been genetically and chemically validated as essential for the survival of the clinically relevant bloodstream form of the parasite.
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The GPI biosynthetic pathway has been extensively studied in both T. brucei and mammalian systems, highlighting differences in both the order of assembly and substrate specificity that can be exploited to produce species-specific inhibitors. The GlcNAc-PI de-N-acetylase is a zinc metalloenzyme that catalyses the second step in biosynthesis of GPI ( Fig. 1) , 6 and has been genetically validated as essential in bloodstream form T. brucei. 3 The use of synthetic substrate analogues has revealed that the human enzyme is more fastidious than the trypanosome enzyme, enabling the design of species-specific substrate-based inhibitors. [7] [8] [9] The substrate analogue approach has shown that the phosphate, 2 0 -NHAc and 3 0 -OH of the substrate GlcNAc-PI are critical for recognition by the T. brucei GlcNAc-PI de-N-acetylase. 10 In contrast, the diacylglycerol is not directly recognised and may be efficiently replaced with an octadecyl chain. 9, 11 Recently, we have shown that substrate-based inhibitors containing the zinc binding moieties hydroxamic acid or carboxylic acid can act as inhibitors of the T. brucei de-N-acetylase. 12, 13 These substrate-based inhibitors do not possess drug-like physiochemical properties and contain too much stereochemical complexity for tractable synthesis. Here, we report our efforts to identify alternative scaffolds for GlcNAc-PI de-N-acetylase inhibitors that resulted in the identification of salicylic hydroxamic acid as an inhibitor with high ligand efficiency.
Materials and methods

Materials
The synthesis of D-glucosamine-a-(1-6)-D-myo-inositol-1-octadecyl phosphate (GlcN-IPC 18 ) has been described previously. 14 solutions determined by measurement of the inositol content by selected ion-monitoring GC-MS. 13 Bloodstream form Trypanosome brucei (variant MITat1.4) was isolated and membranes (cell-free system) prepared as described previously and stored at À80°C.
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Recombinant GST-tagged T. brucei de-N-acetylase (GST-TbGPI12) was expressed and purified as described previously and stored at À80°C. 18 (m/z 672 > 223) was used to calculate the percentage of substrate conversion to product in a given sample. 6 Inhibitor IC 50 values were calculated using a four-parameter fit of eightpoint potency curves derived from three independent experiments, and are quoted with standard deviation.
Trypanosome cell-free system assay
Trypanosome cell-free system assays, where the formation of GPI precursors is monitored by following the incorporation of [ 3 H]-mannose were analysed using high-performance liquid chromatography and fluorography as described previously. (9) 5-Aminosalicylic acid 8 (6.89 g, 45.0 mmol) was suspended in water (60 mL), and TEA (12.4 mL, 90.0 mmol) was added. A solution of Boc 2 O (10.8 g, 90.0 mmol) in dioxane (120 mL) was added, and the reaction was stirred at room temperature overnight. The solvent was removed, and the solid residue suspended in water (20 mL). HCl (3 M) was added until the greyish pink precipitate stopped forming. The precipitate was filtered off and washed with water. The precipitate was dissolved in boiling acetone and hot filtered before being recrystallized twice from acetone to afford the product (8.61 g, 76%) as a white powder, mp 278°C. 
Synthesis of tert-butyl (3-((benzyloxy)carbamoyl)-4-hydroxyphenyl)carbamate (10)
O-Benzylhydroxylamine hydrochloride (3.54 g, 22.2 mmol) was suspended in CHCl 3 (85 mL) and cooled to 0°C, and then TEA (3.21 mL, 23.1 mmol) was added. A solution of compound 9 (5.62 g, 22.2 mmol) in THF (140 mL), DMAP (169 mg, 1.12 mmol) and DCC (5.06 g, 24.4 mmol) was added, and the reaction was stirred for 16 h. The solvent was removed and the solids were resuspended in EtOAc, filtered, and then washed with HCl (1 M, 50 mL), water (50 mL), ammonia (1 M, 2 Â 50 mL) and filtered through cotton wool. The solvent was removed and the crude was dried on to silica then purified by column chromatography (EtOAc/hexane, 0:100 to 1:1) to afford the product (3.63 g, 46%) as a pale yellow powder, mp 102-103°C. 
General method for the synthesis of the amide series
Compound 11 (200 mg, 0.592 mmol), DMAP (cat.) and the acyl chloride (0.592 mmol) were dissolved in THF (2 mL) and DCE (0.5 mL). Pyridine (96 lL, 1.184 mmol) was added, and the reaction stirred for 24 h. The mixture was diluted with DCM (10 mL) and water (10 mL) then stirred vigorously. The mixture was passed through a phase separator, and then the solvent was removed. The crude was recrystallized from MeOH/Et 2 O. Characterisation of compounds 12-19 is reported in the Supplementary data.
General method for amide deprotection
A 0.05 M solution of benzyl-protected amide (12) (13) (14) (15) (16) (17) (18) (19) and AcOH (2 equiv) in MeOH/THF, MeOH or THF, was passed through a H 2 flow reactor (1 mL/min, 30°C, 1 atm) using a 20% Pd(OH) 2 catalyst cartridge. The solvent was removed and the product was recrystallized from THF/MeOH, or washed with THF or MeOH. Characterisation of compounds 20-27 is reported in the Supplementary data.
Results and discussion
Fragment screening
To discover more drug-like scaffolds for zinc-binding de-N-acetylase inhibitors we screened a small focused library of zinc binding fragments. Because we have previously shown that the enzyme may be inhibited by substrate analogues containing hydroxamic acid, N-hydroxyurea or carboxylic acid groups, 12, 13 we selected 26 commercially available fragments, which contained these zinc binding moieties, with an average molecular weight of 220 (Supplemental Table S1 ). We screened the inhibition of recombinant T. brucei de-N-acetylase by the fragments using a mass spectrometry-based activity assay to directly monitor the conversion of the synthetic substrate N-acetyl-D-glucosamine-a-(1-6)-D-myo-inositol-1-octadecyl phosphate (GlcNAc-IPC 18 ) to D-glucosamine-a-(1-6)-D-myo-inositol-1-octadecyl phosphate (GlcNAc-IPC 18 ). The replacement of the diacylglycerol moiety of GlcNAc-PI with a simple C 18 alkyl chain in GlcNAc-IPC 18 has no effect on the substrate recognition, and enables the use of a unique mass-transition to follow the reaction. 6 Initial screening of the fragments at 1 mM in duplicate revealed six compounds with >50% inhibition ( Fig. 2A + D) . However, only one compound showed >50% inhibition at 100 lM (Fig. 2B) . The most potent compound 1 (Fig. 2C) had an IC 50 of 63 ± 4 lM and a molecular weight of 153, giving an impressive ligand efficiency (-RT.lnIC 50 /N non-H atoms ) 16 of À0.57 kcal mol À1 per non-hydrogen atom, which is over one third of the theoretical maximum affinity for organic compounds of where no inhibitors were identified (data not shown). Interestingly, compound 1 (also known as SHAM) has previously been identified as an inhibitor of trypanosome alternative oxidase (TAO), and is toxic in vivo to the clinically relevant bloodstream form T. brucei.
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Inhibition of the T. brucei cell-free system
The ability of 1 to act as an inhibitor of the T. brucei GPI pathway was confirmed using the trypanosome cell-free system (Fig. 3) . Priming the cell-free system with GlcAc-IPC 18 in the presence of GDP-[ 3 H]-mannose stimulates the production of radiolabelled mannosylated GPI intermediates that can be separated by high performance thin-layer chromatography and visualised by fluorography. Priming the cell-free system with GlcNAc-IPC 18 (10 lM) was prevented by incubation with >300 lM of 1 (Fig. 3B) , a five-fold increase over the IC 50 value against the recombinant enzyme. To verify that the decrease in potency was not due to a reduction in potency against the endogenous enzyme compared with the recombinant enzyme, we repeated the mass spectrometry based activity assay with the T. brucei cell-free system. We found that it was necessary to reduce the amount of cell-free system by 40-fold in the mass spectrometry-based assay compared with the radiometric assay to achieve measurements in the linear range for the turnover of GlcNAc-IPC 18 . The potency of compound 1 against the cell-free system with an IC 50 = 66 ± 8 lM (Fig. 3B) was comparable to that against the recombinant enzyme. i The assay used the CHO MS2S cell line, which has a defective de-N-acetylase and expresses the GPI anchored human CD55, functionally complemented by transfection with T. brucei de-N-acetylase. Cells were treated with trypsin, plated onto compound, and GPI biosynthesis monitored by aCD55 ELISA at 48 h.
Structure-activity relationship
Substructure searching identified commercially available analogues of 1 that were screened for activity against in the mass spectrometry based assay against T. brucei cell-free system. Replacement of the hydroxamic acid with carboxylic acid decreased the potency of inhibition, potentially due to the carboxylic acid acting as a less efficient zinc chelator. Removal of the 2-hydroxyl group or substitution with bromide or amine completely abrogated the inhibitory activity, whereas substitution at the 4 0 position with bromine was tolerated ( Table 1) . To further explore the available chemical space, a small array of analogues of compound 1 were synthesised from the literature compound 11
21 by coupling to the 5-NH 2 position with commercially available acid chlorides (Scheme 1). After deprotection of the hydroxamic acid, the majority of compounds showed decreased inhibitory activity compared with 1 ( Table 2 ). The two most potent compounds 20 and 21 had IC 50 values of 45 ± 11 lM and 69 ± 6 lM respectively ( Supplementary Fig. 1 ), comparable to the parent compound albeit with reduced ligand efficiency (À0.30 and À0.29 kcal mol À1 per non-hydrogen atom respectively), suggesting that the 5 0 -amide substitution was tolerated but contributed little to binding.
The structure-activity relationship derived from the data presented here suggest that the 2-OH group of 1 is essential for activity and substitution at the 4-and 5-position is tolerated (Fig. 4) . Comparing 1 with the natural substrate GlcNAc-PI could suggest that 1 is mimicking the GlcNAc moiety, with the 2-OH of 1 mimicking the 3 0 -OH that is essential for substrate recognition. In the proposed reaction mechanism for the de-N-acetylase, the catalytic base D43 assists the nucleophilic attack of a zinc-bound water molecule on the activated acetamidocarbonyl, and the subsequent protonation of the tetrahedral intermediate promotes loss of acetic acid. We propose that 1 could inhibit the enzyme through the hydroxamic acid binding to the catalytic zinc, and replacing both the acetamidocarbonyl and the activated water (Fig. 4) .
Conclusions
We have identified salicylic hydroxamic acid 1 as an inhibitor of T. brucei GlcNAc-PI de-N-acetylase with high ligand efficiency, representing the first non-substrate analogue inhibitor of the trypanosome GPI pathway. Although 1 shows modest potency with an IC 50 of 63 ± 4 lM, it has impressive ligand efficiency of 0.57 kcal mol
À1
per non-hydrogen atom, and thus may be a useful starting point to develop more potent inhibitors. a Inhibition of T. brucei de-N-acetylase (cell-free system). 
